PMID- 30343297
OWN - NLM
STAT- MEDLINE
DCOM- 20190610
LR  - 20190613
IS  - 1421-9662 (Electronic)
IS  - 0001-5792 (Linking)
VI  - 140
IP  - 4
DP  - 2018
TI  - Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center.
PG  - 194-202
LID - 10.1159/000493567 [doi]
AB  - Hodgkin lymphoma (HL) is one of the most curable malignancies. Despite its 
      effectiveness, chemotherapy is often associated with adverse events (AEs) such as 
      nausea, anorexia, and impairment of general well-being. Our objective was to 
      assess the extent of medical cannabis use among HL patients and evaluate its 
      efficacy in controlling chemotherapy-related AEs. Patterns of medical cannabis 
      use and efficacy were evaluated using physician-completed application forms, 
      medical files, and patient-completed questionnaires, for all consecutive adult HL 
      patients treated at the Tel-Aviv Medical Center between June 2010 and November 
      2016. One-hundred and thirty-three patients met the inclusion criteria. The 
      median age of the cohort was 37 years, 53% were male, 46% were diagnosed at an 
      early stage, and 88% achieved a complete response to treatment. Fifty-one 
      patients (38%) used medical cannabis. There were no significant differences in 
      baseline characteristics between cannabis users and nonusers. Cannabis users 
      reported improvement in pain, general well-being, appetite, and nausea in 94, 87, 
      82, and 79% of cases, respectively. Importantly, 81.5% reported a high overall 
      efficacy of cannabis in relieving symptoms. AEs related to cannabis use itself 
      were mild. Thus, medical cannabis use is prevalent in this HL cohort, and appears 
      to be effective in ameliorating chemotherapy-related AEs.
CI  - (c) 2018 S. Karger AG, Basel.
FAU - Sarid, Nadav
AU  - Sarid N
AD  - Department of Hematology, Tel Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel Aviv University, Tel Aviv, Israelnadavsarid@gmail.com.
FAU - Zada, Mor
AU  - Zada M
AD  - Department of Hematology, Tel Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Lev-Ran, Shaul
AU  - Lev-Ran S
AD  - Lev Hasharon Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 
      Tel Aviv, Israel.
FAU - Yashphe, Eva
AU  - Yashphe E
AD  - Department of Hematology, Tel Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Givon, Ido
AU  - Givon I
AD  - Department of Hematology, Tel Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Barzilai, Merav
AU  - Barzilai M
AD  - Department of Hematology, Tel Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Perry, Chava
AU  - Perry C
AD  - Department of Hematology, Tel Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Avivi, Irit
AU  - Avivi I
AD  - Department of Hematology, Tel Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Wolf, Ido
AU  - Wolf I
AD  - Oncology Division, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, 
      Tel Aviv University, Tel Aviv, Israel.
LA  - eng
PT  - Journal Article
DEP - 20181019
PL  - Switzerland
TA  - Acta Haematol
JT  - Acta haematologica
JID - 0141053
RN  - 0 (Medical Marijuana)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Female
MH  - Hodgkin Disease/*drug therapy/pathology
MH  - Humans
MH  - Male
MH  - Medical Marijuana/adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Nausea/etiology
MH  - Neoplasm Staging
MH  - Pain Management
MH  - Prognosis
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cannabis
OT  - Chemotherapy-related adverse events
OT  - Hodgkin lymphoma
EDAT- 2018/10/22 06:00
MHDA- 2019/06/14 06:00
CRDT- 2018/10/22 06:00
PHST- 2018/05/03 00:00 [received]
PHST- 2018/09/10 00:00 [accepted]
PHST- 2018/10/22 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2018/10/22 06:00 [entrez]
AID - 000493567 [pii]
AID - 10.1159/000493567 [doi]
PST - ppublish
SO  - Acta Haematol. 2018;140(4):194-202. doi: 10.1159/000493567. Epub 2018 Oct 19.